HER2 Support Group Forums - View Single Post - MM-302: HERMIONE study

Joan M · 06-09-2016, 02:12 PM

I'm not certain about your reference to tofacitinib. I know that it's used for rheumatoid arthritis. Does it also have another indication for cancer, or in particular HER2+ breast cancer?

Have you ever had any dealings with Merrimack? I know of someone who was in a former trial for MM-302. Two women are still showing a response at 44 and 36 months.

I asked them about using adriamycin (Doxil). That it's a drug that oncologists are steering away from. But they said that that wasn't the case worldwide (which I've heard before from Genentech), and also varies by region in the U.S. And despite its drawbacks, it's still a powerful anticancer drug.

I guess the idea is like Kadcyla. MM-302 is an antibody-drug conjugate delivering the chemotherapy directly to the cancer cells, in order to minimize toxicity to the surrounding healthy tissues. It's designed for those who Perjeta and Kadcyla have failed. So for those never treated with adraimycin, it could be an option.

Joan

06-09-2016, 02:12 PM	#4
Joan M Senior Member Join Date: Oct 2007 Posts: 1,851	Re: MM-302: HERMIONE study I'm not certain about your reference to tofacitinib. I know that it's used for rheumatoid arthritis. Does it also have another indication for cancer, or in particular HER2+ breast cancer? Have you ever had any dealings with Merrimack? I know of someone who was in a former trial for MM-302. Two women are still showing a response at 44 and 36 months. I asked them about using adriamycin (Doxil). That it's a drug that oncologists are steering away from. But they said that that wasn't the case worldwide (which I've heard before from Genentech), and also varies by region in the U.S. And despite its drawbacks, it's still a powerful anticancer drug. I guess the idea is like Kadcyla. MM-302 is an antibody-drug conjugate delivering the chemotherapy directly to the cancer cells, in order to minimize toxicity to the surrounding healthy tissues. It's designed for those who Perjeta and Kadcyla have failed. So for those never treated with adraimycin, it could be an option. Joan __________________ Diagnosed stage 2b in July 2003 (2.3 cm, HER2+, ER-/PR-, 7+ nodes). Treated with mastectomy (with immediate DIEP flap reconstruction), AC + T/Herceptin (off label). Cancer advanced to lung in Jan. 2007 (1 cm nodule). Started Herceptin every 3 weeks. Lung wedge resection April 2007. Cancer recurred in lung April 2008. RFA of lung in August 2008. 2nd annual brain MRI in Oct. 2008 discovered 2.6 cm cystic tumor in left frontal lobe. Craniotomy Oct. 2008 (ER-/PR-/HER2-) followed by targeted radiation (IMRT). Coughing up blood Feb. 2009. Thoractomy July 2009 to cut out fungal ball of common soil fungus (aspergillus) that grew in the RFA cavity (most likely inhaled while gardening). No cancer, only fungus. Removal of tiny melanoma from upper left arm, plus sentinel lymph node biopsy in Feb. 2016. Guardant Health liquid biopsy in Feb. 2016 showed mutations in 4 subtypes of TP53. Repeat of Guardant Health biopsy in Jana. 2021 showed 3 TP53 mutations, BRCA1 mutation and CHEK2 mutation. Invitae genetic testing showed negative for all of these. Living with MBC since 2007. Stopped Herceptin Hylecta (injection) treatment in March 2020. Recent 2021 annual CT of chest, abdomen and pelvis and annual brain MRI showed NED. Praying for NED forever!!